Sarepta Therapeutics (SRPT) Earns Overweight Rating from Piper Jaffray Companies

Wednesday, 14 Mar, 2018's news article titled: "Sarepta Therapeutics plans NDA of Duchenne MD treatment by year end" with publication date: March 12, 2018 was also an interesting one. Piper Jaffray Companies now has a $76.12 price objective on the biotechnology company's stock, down from their prior price objective of $83.00. UBS Group reiterated an outperform rating and issued a $56.51 price target (down from $76.00) on shares of Sarepta Therapeutics in a report on Wednesday, December 27th.

Piper Jaffray Companies reiterated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report released on Monday morning, The Fly reports. The company was downgraded on Tuesday, January 17 by Goldman Sachs. JP Morgan initiated Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 72,956 shares. The firm earned "Outperform" rating on Thursday, March 2 by Leerink Swann. The rating was maintained by Deutsche Bank on Tuesday, June 20 with "Buy". Cardinal Capital Management sold 26,258 shares as the company's stock rose 6.67% with the market.

More recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned "Buy" rating by William Blair on Friday, July 21. (NASDAQ:SRPT) on Friday, October 28 with "Outperform" rating. The stock increased 2.44% or $1.93 during the last trading session, reaching $81.03.

On 11/8/2017 Douglas S Ingram, CEO, bought 38,138 with an average share price of $52.44 per share and the total transaction amounting to $1,999,956.72. One Liberty Properties, Inc. Dana Incorporated (NYSE:DAN) has risen 70.12% since March 12, 2017 and is uptrending. It has underperformed by 15.45% the S&P500. Dnb Asset Management As reported 2.36 million shares.

Lyon Street Capital Llc decreased Grand Canyon Ed Inc (LOPE) stake by 25.87% reported in 2017Q3 SEC filing. Principal Grp invested in 8,873 shares or 0% of the stock. The New York-based Salzhauer Michael has invested 0.35% in the stock.

Sphera Funds Management Ltd, which manages about $700.90M US Long portfolio, upped its stake in Minerva Neurosciences Inc (NASDAQ:NERV) by 151,231 shares to 625,000 shares, valued at $4.75M in 2017Q3, according to the filing.

SemGroup Corporation (NYSE: SEMG) has grabbed attention from the analysts when it experienced a change of 2.91% in the last trading session to close at $22.95. CALA's distance from 20 day simple moving average is -9.19% and distance from 50-Day simple moving average is -11.68%.

Sarepta Therapeutics (NASDAQ:SRPT) opened at $74.36 on Friday. It has outperformed by 80.12% the S&P500.

See which 3 stocks are most likely to make moves following their insider activities. Sarepta Therapeutics's revenue for the quarter was up 961.1% on a year-over-year basis. It dived, as 24 investors sold SRPT shares while 27 reduced holdings.

Investors sentiment increased to 2.88 in Q3 2017. The S&P 500 index fell 3.55 points, or 0.1%, to 2,783.02, with the industrials sector shedding more than 1.2%. As of late, investors have been taking notice of Sarepta Therapeutics, Inc. 63 funds opened positions while 84 raised stakes. US Bancorp DE now owns 4,224 shares of the biotechnology company's stock valued at $235,000 after buying an additional 1,095 shares during the period. Eventide Asset Mngmt Limited Liability holds 161,000 shares. Moreover, Sg Americas Securities Ltd has 0% invested in Sarepta Therapeutics, Inc. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 96.82% since March 12, 2017 and is uptrending. (NASDAQ:SRPT) for 735 shares. Finally, TimesSquare Capital Management LLC purchased a new position in Sarepta Therapeutics during the 3rd quarter worth $21,521,000. (NASDAQ:SRPT). Royal Financial Bank Of Canada reported 0% stake. Parametric Portfolio Assocs Ltd Liability Corp reported 0.01% stake. Perhaps, that suggests something about why 23.90% of the outstanding share supply is held by institutional investors. Jennison Associates LLC increased its holdings in Sarepta Therapeutics by 103.9% during the 3rd quarter. (NASDAQ:SRPT). Legal General Group Public Ltd Co, a United Kingdom-based fund reported 24,396 shares. Tower Ltd Liability Com (Trc) has 0% invested in Sarepta Therapeutics, Inc. Botty Lc has invested 0.03% in Sarepta Therapeutics, Inc. Cubist Systematic Strategies Lc holds 1,786 shares or 0% of its portfolio. Jefferies maintained Sarepta Therapeutics, Inc.

Sarepta Therapeutics, a biopharmaceutical company, which is engaged in the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The 6 months bullish chart indicates low risk for the $5.05 billion company.